GLENMARKNSEGlenmark Pharmaceuticals Limited· PharmaceuticalsMediumNeutral
Announced Fri, 29 May · 21:12 IST

Glenmark Pharmaceuticals Limited has informed the Exchange about Resignation of Director/KMP/SMP

Kmp ResignedManagement Changes View source PDF

GLENMARK · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-5.0%1-day move
₹2293.00
prior close
₹2288.80
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.2-1.4-3.4-3.9-5.0-5.5-4.9-5.6-5.8-6.4-4.4-6.0
Up moveDown movePending
AI summary

Mr. Harish Kuber has resigned from his position as Company Secretary & Compliance Officer at Glenmark Pharmaceuticals, effective May 29, 2026, citing early retirement after more than 9.5 years with the company. He has offered to continue employment for a few months to ensure a smooth transition. Ms. Rashmi Khandelwal has been appointed as the new Company Secretary (Key Managerial Personnel) effective May 30, 2026. She brings over 17 years of experience in corporate governance, regulatory matters, and legal functions across listed entities and financial institutions. Mr. Samir Kazi continues as Executive Vice President and Head – Legal, Compliance & Intellectual Property.

Likely market impact

The resignation appears to be amicable and driven by personal decision rather than any dispute or governance concern. The immediate appointment of a well-qualified replacement with strong governance credentials should provide continuity in compliance and secretarial functions for shareholders.